Trial Profile
A study of Platelet INhibition using a 'POINT of care' platelet function test, following Primary Percutaneous Coronary Intervention for ST elevation myocardial infarction (PINPOINT-PPCI)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Sep 2015
Price :
$35
*
At a glance
- Drugs Bivalirudin (Primary) ; Prasugrel (Primary)
- Indications Embolism and thrombosis; Myocardial infarction
- Focus Pharmacodynamics
- Acronyms PINPOINT-PPCI
- 31 Oct 2012 Status changed from recruiting to completed as reported by ISRCTN.
- 15 Jun 2012 New trial record